Long-acting inhaled β2-agonist therapy in asthma

American Journal of Respiratory and Critical Care Medicine

Volumn 164, Issue 6, 2001, Pages 923-932

  Kips, Johan C ^a   Pauwels, Romain A ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; FLUTICASONE PROPIONATE; FORMOTEROL; GLUCOCORTICOID; LONG ACTING DRUG; MONTELUKAST; PEPTIDOLEUKOTRIENE; SALBUTAMOL; SALIGENIN; SALMETEROL; THEOPHYLLINE;

ASTHMA; BRONCHODILATATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SAFETY; FORCED EXPIRATORY VOLUME; HUMAN; LIPOPHILICITY; MONOTHERAPY; PATHOPHYSIOLOGY; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

EID: 0035883494     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.164.6.2010107     Document Type: Review

References (180)

1. Salmeterol, a new long acting inhaled beta 2 adrenoceptor agonist: Comparison with salbutamol in adult asthmatic patients
2. Formoterol fumarate, a new beta 2-adrenoceptor agonist: Acute studies of selectivity and duration of effect after inhaled and oral administration
3. The beta-adrenoceptor
4. Why are long-acting beta-adrenoceptor agonists long-acting?
5. Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics
6. Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma
7. Effects of 22 months of treatment with inhaled corticosteroids and/or beta-2-agonists on lung function, airway responsiveness, and symptoms in children with asthma
8. A comparison of beclomethasone, salmeterol, and placebo in children with asthma
9. One year treatment with salmeterol compared with beclomethasone in children with asthma
10. Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma
11. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid
12. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids
13. A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma
14. A placebo-controlled, crossover comparison of salmeterol and salbutamol in patients with asthma
15. Asthma control during long-term treatment with regular inhaled salbutamol and salmeterol
16. A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma
17. Comparison of addition of theophylline to inhaled steroid with doubling of the dose of inhaled steroid in asthma
18. Montelukast added to inhaled beclomethasone in treatment of asthma
19. The efficacy and safety of salmeterol compared to theophylline: Meta-analysis of nine controlled studies
20. Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma
21. Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast
22. Potential masking effects of salmeterol on airway inflammation in asthma
23. A long-term study of the antiinflammatory effect of low-dose budesonide plus formoterol versus high-dose budesonide in asthma
24. Efficacy and safety of salmeterol in childhood asthma
25. Regular inhaled beta agonist in asthma: Effects on exacerbations and lung function
26. Effect of inhaled formoterol and budesonide on exacerbations of asthma
27. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA)
28. Effect of long-term treatment with salmeterol on asthma control: A double blind, randomised crossover study
29. Salmeterol reduces the need for inhaled corticosteroid in steroid-dependent asthmatics
30. Salmeterol and fluticasone propionate (50/250 μ) administered via combination Diskus inhaler: As effective as when given via separate Diskus inhalers
31. Salmeterol/fluticasone propionate (50/500 μ) in combination in a Diskus inhaler (Seretide) is effective and safe in the treatment of steroid-dependent asthma
32. Efficacy and safety of a new single inhaler product, containing both budesonide and formoterol, in adult asthma
33. Combined salmeterol 50 μ and fluticasone propionate 250 μ in the diskus device for the treatment of asthma
34. Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: A randomized, double-blind, placebo-controlled trial
35. Symbicort (Budesonide and formoterol in a single inhaler) administered once daily is effective in mild to moderate asthma
36. Symbicort (Budesonide and formoterol in a single inhaler) is a more effective treatment than fluticasone in asthma patients
37. Symbicort (Budesonide and formoterol in a single inhaler) is more effective than increasing the dose of inhaled corticosteroid in mild asthma
38. Advair/Seretide (250μg/50μg BID) shows exacerbation benefit over Budesonide 800 μg + Formoterol 12μg twice daily in moderate-severe asthma
39. Protective effect and duration of action of inhaled formoterol and salbutamol on exercise-induced asthma in children
40. Inhaled formoterol in the prevention of exercise-induced bronchoconstriction in asthmatic children
41. Pilgrim's progress: The effect of salmeterol in older children with chronic severe asthma
42. Salmeterol xinafoate in children on high dose inhaled steroids
43. Long-acting beta(2)-agonists in management of childhood asthma: A critical review of the literature
44. Long-term circadian effects of salmeterol in asthmatic children treated with inhaled corticosteroids
45. Addition of salmeterol versus doubling the dose of beclomethasone in children with asthma
46. Effects of treatment on airway inflammation and thickening of basement membrane reticular collagen in asthma: A quantitative light and electron microscopic study
47. Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma
48. A comparative study of the effects of an inhaled corticosteroid, budesonide, and a beta 2-agonist, terbutaline, on airway inflammation in newly diagnosed asthma: A randomized, double-blind, parallel-group controlled trial
49. Prolonged protection against methacholine-induced bronchoconstriction by the inhaled beta 2-agonist formoterol
50. Time course of bronchodilating effect of inhaled formoterol, a potent and long acting sympathomimetic
51. The effect of inhaled salmeterol on methacholine responsiveness in subjects with asthma up to 12 hours
52. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: Onset of action, duration of effect and potency
53. Comparison of the effects of salmeterol and formoterol on airway tone and responsiveness over 24 hours in bronchial asthma
54. Salmeterol versus formoterol in patients with moderately severe asthma: Onset and duration of action
55. Prolonged effect of inhaled salmeterol against exercise-induced bronchospasm
56. Duration of action of formoterol and salbutamol dry-powder inhalation in prevention of exercise-induced asthma in children
57. Formoterol via Turbuhaler gave better protection than terbutaline against repeated exercise challenge for up to 12 hours in children and adolescents
58. Long acting inhaled beta2-agonists: Anti-inflammatory effects not evident during treatment of day to day asthma
59. Intranasal salmeterol inhibits allergen-induced vascular permeability but not mast cell activation or cellular infiltration
60. Effects of formoterol on histamine induced plasma exudation in induced sputum from normal subjects
61. The effect of salmeterol on the early- and late-phase reaction to bronchial allergen and postchallenge variation in bronchial reactivity, blood eosinophils, serum eosinophil cationic protein, and serum eosinophil protein X
62. Comparison of the effects of salmeterol and salbutamol on clinical activity and eosinophil cationic protein serum levels during the pollen season in atopic asthmatics
63. A comparative study in atopic subjects with asthma of the effects of salmeterol and salbutamol on allergen-induced bronchoconstriction, increase in airway reactivity, and increase in urinary leukotriene E4 excretion
64. Formoterol compared with beclomethasone and placebo on allergen-induced asthmatic responses
65. Effect of salmeterol compared with beclomethasone on allergen-induced asthmatic and inflammatory responses
66. Effect of a single dose of salmeterol on the increase in airway eosinophils induced by allergen challenge in asthmatic subjects
67. Effect of eight weeks of treatment with salmeterol on bronchoalveolar lavage inflammatory indices in asthmatics
68. The effect of salmeterol on nocturnal symptoms, airway function, and inflammation in asthma
69. The effects of regular inhaled formoterol, budesonide, and placebo on mucosal inflammation and clinical indices in mild asthma
70. The long-acting beta2-agonist salmeterol xinafoate: Effects on airway inflammation in asthma
71. 2 agonist, assessed in airway biopsies and bronchoalveolar lavage in asthma
72. Beta-adrenergic agonists attenuate fibroblast-mediated contraction of released collagen gels
73. Effects of glucocorticoids and beta-adrenoceptor agonists on the proliferation of airway smooth muscle
74. Inhibitory effects of formoterol on platelet-activating factor induced eosinophil chemotaxis and degranulation
75. Inhibition by salmeterol of increased vascular permeability and granulocyte accumulation in guinea-pig lung and skin
76. Regular albuterol, nedocromil sodium, and bronchial inflammation in asthma
77. Effects of terbutaline and budesonide on sputum cells and bronchial hyperresponsiveness in asthma
78. Salmeterol enhances the inhibitory activity of dexamethasone on allergen-induced blood mononuclear cell activation
79. 2-agonists and corticosteroids on tumor necrosis factor-α-induced interleukin-8 release from cultured human airway smooth-muscle cells
80. Budesonide and formoterol exert an additive effect on the inhibition of ICAM-1 and VCAM-1 upregulation and GM-CSF production of human lung fibroblasts
81. Salmeterol facilitation of fluticasone-induced apoptosis in eosinophils of asthmatics pre-and post-antigen challenge
82. Additive inhibition of formoterol and budesonide on GM-CSF expression in cultured bronchial epithelial cells
83. Bronchial biopsy study in asthmatics treated with low and high dose fluticasone propionate (FP) compared to low dose FP combined with salmeterol
84. Beta-adrenergic receptors and their regulation
85. Molecular mechanisms of membrane receptor desensitization
86. 2 adrenergic receptor-Src protein kinase complexes
87. Role of cyclo-oxygenase-2 induction in interleukin-1beta induced attenuation of cultured human airway smooth muscle cell cyclic AMP generation in response to isoprenaline
88. 2AR-adenylyl cyclase pathway in human airway smooth muscle
89. Autocrine cytokine signaling mediates effects of rhinovirus on airway responsiveness
90. Mechanisms of impaired β-adrenoceptor-induced airway relaxation by interleukin-1β in vivo in the rat
91. Prostanoids mediate IL-1β-induced β-adrenergic hyporesponsiveness in human airway smooth muscle cells
92. Interactions of glucocorticoids and beta 2-agonists
93. Regulation of beta-adrenergic receptors by steroid hormones
94. sα protein expression in airway smooth muscle
95. Glucocorticosteroids increase beta 2-adrenergic receptor transcription in human lung
96. 2-adrenergic receptor function in human nasal mucosa
97. A bolus of inhaled budesonide rapidly reverses airway subsensitivity and β2-adrenoceptor down-regulation after regular inhaled formoterol
98. Concomitant administration of low-dose prednisolone protects against in vivo β2-adrenoceptor subsensitivity induced by regular formoterol
99. Long-term effects of a long-acting beta 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma
100. Regular formoterol treatment in mild asthma: Effect on bronchial responsiveness during and after treatment
101. Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol
102. Bronchodilator subsensitivity after chronic dosing with eformoterol in patients with asthma
103. Salmeterol tachyphylaxis in steroid treated asthmatic subjects
104. Effects of treatment with formoterol on bronchoprotection against methacholine
105. Tolerance to the protective effects of salmeterol on methacholine-induced bronchoconstriction: Influence of inhaled corticosteroids
106. Subsensitivity to bronchoprotection against adenosine monophosphate challenge following regular once-daily formoterol
107. An inhaled glucocorticoid does not prevent tolerance to the bronchoprotective effect of a long-acting inhaled beta 2-agonist
108. Effects of the long acting beta agonist formoterol on asthma control in asthmatic patients using inhaled corticosteroids
109. Sustained bronchoprotection, bronchodilatation, and symptom control during regular formoterol use in asthma of moderate or greater severity
110. Transcription factors and asthma
111. Transcription: A growing coactivator network
112. Beta-adrenoceptor agonists interfere with glucocorticoid receptor DNA binding in rat lung
113. Switching of the coupling of the beta2-adrenergic receptor to different G proteins by protein kinase A
114. 2- adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells
115. The interaction between salmeterol and beta 2-adrenoceptor agonists with higher efficacy on guinea-pig trachea and human bronchus in vitro
116. Systemic effects of formoterol and salmeterol: A dose-response comparison in healthy subjects
117. Evaluation of the beta 2 adrenoceptor agonist/antagonist activity of formoterol and salmeterol
118. Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients
119. Relaxant effects and durations of action of formoterol and salmeterol on the isolated human bronchus
120. 2 adrenoceptor agonists: Interactions in human contracted bronchi
121. Correlation of cyclic AMP accumulation and relaxant actions of salmeterol and salbutamol in bovine tracheal smooth muscle
122. 2 adrenoceptor agonists on changes in intracellular cyclic AMP and on cyclic AMP driven gene expression in cultured human airway smooth muscle cells
123. Estimation of the efficacy and affinity of the beta 2-adrenoceptor agonist salmeterol in guinea-pig trachea
124. Differential effects of salbutamol and salmeterol on human eosinophil responses
125. Paradoxical blockade of beta adrenergically mediated inhibition of stimulated eosinophil secretion by salmeterol
126. Bronchoprotection by salmeterol: Cell stabilization or functional antagonism? Comparative effects on histamine- and AMP-induced bronchoconstriction
127. Differential effect of formoterol on adenosine monophosphate and histamine reactivity in asthma
128. Comparison of salmeterol and albuterol-induced bronchoprotection against adenosine monophosphate and histamine in mild asthma
129. Salmeterol-induced desensitization, internalization and phosphorylation of the human beta2-adrenoceptor
130. Repetitive endocytosis and recycling of the beta 2-adrenergic receptor during agonist-induced steady state redistribution
131. Different bronchodilating effect of salmeterol and formoterol in an adult asthmatic
132. Bronchodilating effect of formoterol but not of salmeterol in two asthmatic patients
133. Comparison of the effects of salmeterol and formoterol in patients with severe asthma
134. Salmeterol does not compromise the bronchodilator response to albuterol during acute episodes of asthma
135. In vivo effect of albuterol on methacholine-contracted bronchi in conjunction with salmeterol and formoterol
136. Exacerbations of asthma: A descriptive study of 425 severe exacerbations
137. Treatment of mild persistent asthma with low doses of inhaled budesonide alone or in combination with formoterol
138. 2-agonists: Eformoterol via Turbohaler and salmeterol via pressurized metered dose inhaler or Accuhaler, in mild to moderate asthmatics
139. 2-adrenoceptor polymorphisms and asthma
140. Mutations in the gene encoding for the beta 2-adrenergic receptor in normal and asthmatic subjects
141. 2-adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells
142. Association between beta 2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitisation in moderately severe stable asthmatics
143. 2-adrenoceptor polymorphism
144. 2-adrenoceptor regulation and bronchodilator sensitivity after regular treatment with formoterol in subjects with stable asthma
145. 2-adrenergic receptor polymorphisms with severe asthma
146. 2 adrenoceptor polymorphism
147. Comparison of formoterol, salbutamol and salmeterol in methacholine-induced severe bronchoconstriction
148. Tolerability to high doses of formoterol and terbutaline via Turbuhaler for 3 days in stable asthmatic patients
149. Relative systemic dose potency and tolerability of inhaled formoterol and salbutamol in healthy subjects and asthmatics
150. Comparison of formoterol and terbutaline for as-needed treatment of asthma: A randomised trial
151. Formoterol 4.5 μg, used as needed via Turbuhaler was as safe and well tolerated as terbutaline 0.5 mg
152. Formoterol μg via Turbuhaler was safe in patients with acute bronchoconstriction
153. Anti-inflammatory activity of salmeterol: Down-regulation of cytokine production
154. Effects of beta2 adrenoceptor agonists on T-cell subpopulations
155. Inhibitory actions of salmeterol on human airway macrophages and blood monocytes
156. The effects of beta 2-adrenoceptor agonists and a corticosteroid, budesonide, on the secretion of inflammatory mediators from monocytes
157. Salmeterol inhibits anaphylactic histamine release from guinea-pig isolated mast cells
158. Effects of beta 2-adrenergic agonists on isolated guinea pig lung mast cells
159. 2-agonists: Inhibition of TNF-alpha release from human mast cells
160. Salmeterol: A potent and long-acting inhibitor of inflammatory mediator release from human lung
161. Salmeterol is a competitive antagonist at beta-adrenoceptors mediating inhibition of respiratory burst in guinea-pig eosinophils
162. Evidence that the eosinophil is a cellular target for the inhibitory action of salmeterol on eosinophil recruitment in vivo
163. Anti-inflammatory effects of a short-acting and a long-acting beta 2-adrenoceptor agonist in guinea pig skin
164. Comparison of the anti-inflammatory properties of formoterol, salbutamol and salmeterol in guinea-pig skin and lung
165. Delayed eosinophil apoptosis in asthma
166. Anti-inflammatory, membrane-stabilizing interactions of salmeterol with human neutrophils in vitro
167. Inhibition of neutrophil and eosinophil adhesion to venules of rat trachea by beta 2-adrenergic agonist formoterol
168. Increased cAMP levels in stimulated neutrophils inhibit their adhesion to human bronchial epithelial cells
169. Beta 2-adrenoceptor agonists inhibit NANC neural bronchoconstrictor responses in vitro
170. Formoterol and salbutamol inhibit bradykinin- and histamine-induced airway microvascular leakage in guinea-pig
171. The beta 2-adrenergic receptor agonist formoterol reduces microvascular leakage by inhibiting endothelial gap formation
172. Long duration and high potency of antiexudative effects of formoterol in guinea-pig tracheobronchial airways
173. The effects of formoterol on plasma exudation produced by a localized acute inflammatory response to bradykinin in the tracheal mucosa of rats in vivo
174. Differential effects of salmeterol on lung endothelial and epithelial leakage in sheep
175. Budesonide and formoterol inhibit ICAM-1 and VCAM-1 expression of human lung fibroblasts
176. Functional and binding characteristics of long-acting beta 2-agonists in lung and heart
177. Effect of short- and long-acting beta 2-adrenoceptor agonists on pulmonary beta 2-adrenoceptor expression in human lung
178. 2-adrenoceptor - Regulation and bronchodilatation
179. Formoterol on airway smooth muscle and human lung mast cells: A comparison with salbutamol and salmeterol